Sakditad Saowapa/X
Jun 23, 2025, 09:26
Sakditad Saowapa Shares ISTH 2025 Highlights on TPO-RAs and Chemotherapy-Induced Thrombocytopenia
Sakditad Saowapa, Oncologist at UI Holden Comprehensive Cancer Center, shared a post on X:
“ISTH 2025 Highlights.
Learned so much from the session “Thrombopoietin: A journey from bench to bedside” moderated by Dr. Manuel Carcao!
Key takeaways on TPO/TPO-RAs:
- Role in CIT (Chemotherapy-Induced Thrombocytopenia)
- Applications in AML, MDS, stem cell collection, liver disease, HCV
- Emerging use of Hetrombopag
- Improved platelet recovery
- Reduced chemo delays
- Higher dose intensity
Trials showed romiplostim and hetrombopag may significantly impact outcomes by preventing dose reductions and delays.
NCCN 2025 CIT guideline highlights:
- Consider TPO-RA in platelet <100K for ≥3–4 weeks post-chemo
- Romiplostim: 2–10 mcg/kg/week
Impressive science, powerful clinical relevance.”
More posts featuring Sakditad “Tew” Saowapa.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 23, 2025, 09:19
Jun 23, 2025, 08:55
Jun 23, 2025, 08:55
Jun 23, 2025, 07:59